Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab DOI Creative Commons
Nishita Tripathi, Luís Meza, Nicolas Sayegh

et al.

Kidney Cancer, Journal Year: 2023, Volume and Issue: 7(1), P. 137 - 145

Published: Dec. 18, 2023

Background: Ipilimumab plus nivolumab is approved as a first-line treatment for intermediate or poor risk metastatic renal cell carcinoma (mRCC). However, ∼35% of patients progress within six months on ipilimumab nivolumab, and no validated genomic biomarkers predict the benefit. In this study, we explore transcriptomic differences among with clear mRCC who either did not experience clinical benefit from therapy. Method: Patients IMDC scores, available tumor whole exome with/without transcriptome sequencing before starting systemic therapy were included. developed complete response, partial stable disease at least after initiating categorized into ‘clinical benefit’ group, whereas rest classified ‘no benefit.’ Genomic alteration frequencies between groups assessed chi-square test. Differentially expressed genes gene sets identified via DeSeq2 GSEA v4.2.3, respectively. Result: 53 (37 16 benefit) eligible No significant difference was found in these groups. Baseline data 14 (9 5 benefit). The apical surface pathways downregulated by KRAS signaling enriched inflammatory group. Conclusion: These findings suggest that specific expression RNA could serve potential biomarker response to

Language: Английский

Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks DOI Creative Commons
Lingjiao Meng,

Haotian Wu,

Jiaxiang Wu

et al.

Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(1)

Published: Jan. 4, 2024

Abstract Current treatment strategies for cancer, especially advanced are limited and unsatisfactory. One of the most substantial advances in cancer therapy, last decades, was discovery a new layer immunotherapy approach, immune checkpoint inhibitors (ICIs), which can specifically activate cells by targeting checkpoints. Immune checkpoints type immunosuppressive molecules expressed on cells, regulate degree activation avoid autoimmune responses. ICIs, such as anti-PD-1/PD-L1 drugs, has shown inspiring efficacy broad applicability across various cancers. Unfortunately, not all patients benefit remarkably from overall response rates to ICIs remain relatively low types. Moreover, primary acquired resistance pose serious challenges clinical application immunotherapy. Thus, deeper understanding molecular biological properties regulatory mechanisms is urgently needed improve options fo r current therapies. Recently, circular RNAs (circRNAs) have attracted increasing attention, only due their involvement aspects hallmarks, but also impact shaping tumor microenvironment. In this review, we systematically summarize status existing roles circRNAs Meanwhile, aim settle issue an evidence-oriented manner that involved hallmarks effects

Language: Английский

Citations

59
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials DOI
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel

et al.

Nature Reviews Clinical Oncology, Journal Year: 2024, Volume and Issue: 21(6), P. 468 - 482

Published: April 10, 2024

Language: Английский

Citations

31
High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome DOI Creative Commons
Nithya Krishnamurthy, Daisuke Nishizaki, Scott M. Lippman

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2024, Volume and Issue: 16

Published: Jan. 1, 2024

CTLA-4 impedes the immune system's antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents - ipilimumab tremelimumab both used together with anti-PD-1/PD-L1 agents.

Language: Английский

Citations

10
Mathematical modeling of interactions between colon cancer and immune system with a deep learning algorithm DOI Creative Commons
Elham Raeisi, Mehmet Yavuz, Mohammadreza Khosravifarsani

et al.

The European Physical Journal Plus, Journal Year: 2024, Volume and Issue: 139(4)

Published: April 24, 2024

Abstract Colon cancer is a complex disease with genetically unstable cell lines. In order to better understand the complexity of colon cells and their metastatic mechanisms, we develop mathematical model in this study. The based on system fractional-order differential equations Fractional-Cancer-Informed Neural Networks (FCINN). captures dynamic network interactions between dendritic (DCs), cytotoxic T-cells (CD $$8^+$$ 8+ ), helper $$4^+$$ xmlns:mml="http://www.w3.org/1998/Math/MathML">4+ through fractional equations. By varying 0 1, can classify patients into different groups immune patterns. goal paper identify patterns behaviors, as well parameters that play an important role metastasis, control, or elimination model. However, several are difficult estimate patient-specific manner. To address challenge, use FCINN effective deep-learning tool for parameter estimation numerical simulation Our findings suggest most factors controlling progression preventing metastasis initial number cells, inhibiting rates tumor by DCs, source activation DCs. These DCs be used immunotherapy control treatment cancer.

Language: Английский

Citations

10
Microenvironment-based immunotherapy in oral cancer: a comprehensive review DOI

Hassan Mivehchi,

Aisan Eskandari-Yaghbastlo,

Masumeh Ghazanfarpour

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(5)

Published: March 28, 2025

Language: Английский

Citations

1
Advances in adoptive T-cell therapy for metastatic melanoma DOI
Aparimita Das, Aruni Ghose,

Kevin Naicker

et al.

Current Research in Translational Medicine, Journal Year: 2023, Volume and Issue: 71(3), P. 103404 - 103404

Published: July 1, 2023

Language: Английский

Citations

21
Metastasis organotropism in colorectal cancer: advancing toward innovative therapies DOI Creative Commons
Kai He,

Zhihan Wang,

Maochao Luo

et al.

Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Sept. 9, 2023

Abstract Distant metastasis remains a leading cause of mortality among patients with colorectal cancer (CRC). Organotropism, referring to the propensity target specific organs, is well-documented phenomenon in CRC, liver, lungs, and peritoneum being preferred sites. Prior establishing premetastatic niches within host CRC cells secrete substances that promote metastatic organotropism. Given pivotal role organotropism metastasis, comprehensive understanding its molecular underpinnings crucial for biomarker-based diagnosis, innovative treatment development, ultimately, improved patient outcomes. In this review, we focus on metabolic reprogramming, tumor-derived exosomes, immune system, cell-organ interactions outline mechanisms organotropic metastasis. Furthermore, consider prospect targeting therapy.

Language: Английский

Citations

19
Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets DOI Creative Commons

Tatiana Vilela,

Sofia Valente,

Jorge Correia

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: 1879(5), P. 189144 - 189144

Published: June 22, 2024

The role of inflammation in cancer is a topic that has been investigated for many years. As established, emerges as defining characteristic cancer, presenting itself compelling target therapeutic interventions the realm oncology. Controlling tumor microenvironment (TME) gained paramount significance, modifying not only effectiveness immunotherapy but also modulating outcomes and prognoses standard chemotherapy other anticancer treatments. Immunotherapy surfaced central focus within domain treatments, using immune checkpoint inhibitors therapy. Immune checkpoints their influence on dynamic are presently under investigation, aiming to ascertain viability across several types. Cancer presents significant challenge humans cats, where female breast ranks most prevalent malignancy feline mammary carcinoma stands third frequent. This review seeks summarize data about cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), lymphocyte activation gene-3 (LAG-3), programmed cell death protein-1 (PD-1), V-domain Ig suppressor T (VISTA), T-cell immunoglobulin mucin 3 (TIM-3) respective ongoing investigations prospective targets therapy human while outlining findings from studies reported (FMC), strengthening rationale employing FMC representative model exploration cancer.

Language: Английский

Citations

5
Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer DOI

Shaukat Ali,

Mahnoor Arshad,

Muhammad Summer

et al.

Journal of Oncology Pharmacy Practice, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Objective There was a dire need to construct review of the recent developments on Immune checkpoint inhibitors (ICIs), CAR T Cells, and other approaches for cell-based immunotherapeutic strategies against cancer as has become one most fatal diseases that is responsible causing several deaths per annum. Data sources Multiple published data acquired from high-impact factor journal articles. summary clinical have been in use today such radiotherapy, chemotherapy immunotherapy treat different types. Among novel management strategies, role by cells immensely important. Cancer revolutionized treatment it basically utilizes body's immune system cancer. At forefront this revolution, are considered fundamental components system. Conclusions The current explores therapeutic potential fight applying various ICIs (PD-1/PD-L1, CTLA-4, TIGIT, BTLA, TIM3, LAG3) adoptive cell therapy. stimulate existing anti-tumor T-cell response way removing inhibitors. On hand, therapy (ACT) patient's modified identify attack tumor cells. Furthermore, also highlights significant successes observed with these therapies, notably PD-1 blockade tumors. Moreover, vaccination, bispecific antibodies cytokine enhance antitumor activity. Therapeutic vaccines expose tumor-associated antigens training then cells, showing promising results types cancers prostate melanoma. While, accompanied cytokines interleukin-2 (IL-2) activity proliferation, thereby boosting overall response. Lastly, future immunotherapy, envisioning advancements design gene editing techniques can efficacy across broader spectrum cancers.

Language: Английский

Citations

0
The role of exosomes in bladder cancer immunotherapy DOI Creative Commons
Mohammad Mousaei Ghasroldasht, Piyush K. Agarwal

Journal of the National Cancer Center, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Citations

0